Available via license: CC BY 4.0
Content may be subject to copyright.
1
Prevalence of amyloid blood clots in COVID-19 plasma
Etheresia Pretorius1* Chantelle Venter1, Gert Jacobus Laubscher2, Petrus Johannes
Lourens2 , Janami Steenkamp2, Douglas B Kell1,4,5*,
1* Department of Physiological Sciences, Faculty of Science, Stellenbosch University,
Stellenbosch, Private Bag X1 Matieland, 7602, South Africa
2 Stellenbosch MediClinic, Elsie du Toit street, Stellenbosch 7600, South Africa
3 PathCare Laboratories, PathCare Business Centre, Neels Bothma Street, N1 City,7460,
South Africa
4 Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and
Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St,
Liverpool L69 7ZB, UK
5The Novo Nordisk Foundation Centre for Biosustainability, Building 220, Kemitorve
Technical University of Denmark, 2800 Kongens Lyngby, Denmark
*Corresponding authors:
*Etheresia Pretorius
Department of Physiological Sciences, Stellenbosch University, Private Bag X1 Matieland,
7602, SOUTH AFRICA
resiap@sun.ac.za
http://www.resiapretorius.net/
ORCID: 0000-0002-9108-2384
*Douglas B. Kell
Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and
Integrative Biology, University of Liverpool, Crown St, Liverpool L69 7ZB, UK
dbk@liv.ac.uk
http://dbkgroup.org/
ORCID: 0000-0001-5838-7963
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
2
Prevalence of amyloid blood clots in COVID-19 plasma ................................................. 1
Keywords. COVID-19 – coagulopathies – amyloid – pathologies ............................... 2
Abstract ................................................................................................................................. 3
Introduction ........................................................................................................................... 3
Methods ................................................................................................................................ 4
Ethical considerations ......................................................................................................... 4
Patient sample ..................................................................................................................... 4
Results .................................................................................................................................. 5
Discussion .......................................................................................................................... 10
DECLARATIONS ............................................................................................................... 12
Funding ............................................................................................................................... 12
Competing interests .......................................................................................................... 12
Consent for publication ..................................................................................................... 12
References ......................................................................... Error! Bookmark not defined.
Keywords. COVID-19 – coagulopathies – amyloid – pathologies
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
3
Abstract
The rapid detection of COVID-19 uses genotypic testing for the presence of SARS-Cov-2 virus
in nasopharyngeal swabs, but it can have a poor sensitivity. A rapid, host-based physiological
test that indicated whether the individual was infected or not would be highly desirable.
Coagulaopathies are a common accompaniment to COVID-19, especially micro-clots within
the lungs. We show here that microclots can be detected in the native plasma of COVID-19
patient, and in particular that such clots are amyloid in nature as judged by a standard
fluorogenic stain. This provides a rapid and convenient test (P<0.0001), and suggests that the
early detection and prevention of such clotting could have an important role in therapy.
Introduction
The standard method for detecting infection with SARS-CoV-2 leading to COVID-19
disease involves a genotypic (PCR) test for the virus on nasopharyngeal swabs, but it
is not particularly pleasant and can have poor sensitivity (1-4). What would be
desirable is a rapid and phenotypic test on the host that indicates the presence, and if
possible the severity, of the consequences of infection. Presently, the standard
method for this is based on CT chest scans for pneumonia, which have high sensitivity
but lower specificity (see (5-7) and below), but this is neither cheap nor universally
available.
It is widely recognised (8-13) that extensive blood clotting has a major role in the
pathophysiology of COVID-19 disease severity and progression, yet so can excessive
bleeding (14, 15). The solution to this apparent paradox lies in the recognition (16) that
these phases are separated in time, with excessive clotting preceding the later
bleeding that is mediated by the clotting-induced depletion of fibrinogen and of von
Willebrand factor (VWF). This first phase is accompanied by partial fibrinolysis of the
formed clots, and an extent of D-dimer formation that is predictive of clinical outcomes
(17). These features, together with the accompanying decrease in platelets
(thrombocytopaenia), leads to the subsequent bleeding. Thus it is suggested that the
application of suitably monitored levels of anti-clotting agents in the earlier phase
provides for a much better outcome (10, 16).
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
4
As well as the extent of clotting, including the life-threatening disseminated
intravascular coagulation (DIC) (12), a second issue pertains to its nature. Some years
ago, we discovered that in the presence of microbial cell wall components (18, 19),
and in a variety of chronic, inflammatory diseases (20-22) (including sepsis (23)),
blood fibrinogen can clot into an anomalous, amyloid form (24). These forms are easily
detected by a fluorogenic stain such as thioflavin T, or the so-called Amytracker stains
(25). In all cases, however, these experiments were performed in vitro using relevant
plasma, with clotting being induced by the addition of thrombin. This was also the case
for plasma from COVID-19 patients, but the signals were so massive that they were
essentially off the scale. However, as we report here, the plasma of COVID-19 patients
carries a massive load of preformed amyloid clots (with no thrombin being added), and
this therefore provides a rapid and convenient test for COVID-19.
Methods
Ethical considerations
Ethical approval for blood collection and analysis of the patients with COVID-19 and
healthy individuals, was given by the Health Research Ethics Committee (HREC) of
Stellenbosch University (reference number: 9521). This laboratory study was carried
out in strict adherence to the International Declaration of Helsinki, South African
Guidelines for Good Clinical Practice and the South African Medical Research Council
(SAMRC), Ethical Guidelines for research. Oral consent was obtained from all
participants prior to any sample collection.
Patient sample
Covid-19 patients
20 COVID-19-positive samples (11 males and 9 females) were obtained and blood
samples collected before treatment was embarked upon. Blood samples were
collected by JS. Platelet poor plasma (PPP) prepared and stored at -80°C, until
fluorescent microscopy analysis.
Healthy samples
Our healthy sample was 10 age-matched controls (4 males and 6 females), previously
collected and stored in our plasma repository. They were non-smokers, with CRP
levels within healthy ranges, and not on any anti-inflammatory medication.
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
5
Lung CT scans
Amongst the COVID-19 patient sample 10 patients were admitted, but stabilized and
blood drawn and sent home for observation. Where patients were clinically deemed
as moderate or severely ill, CT scans of the patients were performed to determine the
severity of the lung pathology. We divided our sample into mild disease (no CT scan)
and moderate to severely ill. The CT scan and severity score (26) confirmed moderate
to severely ill patients according to the ‘ground glass’ opacities in the lungs.
Fluorescent Microscopy of patient whole blood and platelet poor plasma
Fluorescent (anomalous) amyloid signals present in PPP from COVID-19 patients and
healthy age-matched individuals were studied using PPP that was stored at -80°C.
On the day of analysis, PPP was thawed and incubated with thioflavin T (ThT; 5 µM
final concentration). Following this, the sample was incubated for 30 min (protected
from light) at room temperature. PPP smears were then created by transferring a small
volume (5 µl) of the stained PPP sample to a microscope slide (similar methods were
followed to create a blood smear). A cover slip was placed over the prepared smear
and viewed using a Zeiss AxioObserver 7 fluorescent microscope with a Plan-
Apochromat 63x/1.4 Oil DIC M27 objective. Unstained samples were also prepared
with both healthy and COVID-19 PPP, to assess any autofluorescence. Micrograph
analysis was done using ImageJ (version 2.0.0-rc-34/1.5a). The % area of amyloid
were calculated using the thresholding method. Statistical analysis was done using
Graphpad, Prism 8 (version 8.4.3).
Results
Age-matched COVID-19 (average age 49.9y) and healthy individuals (49.05y), were
used in this analysis (p= 0.065). Figure 1 shows representative CT scans of four of the
COVID-19 patients. Raw data is shared in
https://1drv.ms/u/s!AgoCOmY3bkKHirZOu5YKPlq1x5f1AQ?e=xmWGKm
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
6
Figure 1A to D: Representative CT scans of a COVID-19 patient. Yellow arrows show
ground glass opacities.
Figure 2 to 4 show representative fluorescent micrographs of PPP from healthy and
COVID-19 individuals. In healthy PPP smears (Figure 2), very little ThT fluorescent
signal is visible, while in COVID-19 individuals (Figure 3), abundant amyloid signal is
noted. Note that these signals were as received; no thrombin was added to induce
clotting. Figure 4 shows the additional presence of fibrous or cellular deposits in the
PPP smears. From their appearance, some of these deposits seem to have originated
from endothelial cells. There have been reports of extensive endotheliopathy in
COVID-19 patients (27). Figure 5A and B show box plots of the % area of amyloid
signal calculated from representative micrographs of each individual. A nonparametric
one-way ANOVA test (Kruskal-Wallis test) between all three groups showed a highly
significant difference (p = <0.0001). However, a Mann-Whitney analysis between the
mild and the moderate to severe COVID-19 individuals showed no significant
difference (p = 0.554). Amyloid formation in plasma is therefore present in the early
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
7
stages of COVID-19, when the patients are sufficiently unwell to visit the hospital and
in need of stabilization.
Figure 2 A to D): Representative fluorescent micrographs of platelet poor plasma
from healthy individuals. Some signals are very slight, as shown by the arrows in A).
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
8
Figure 3A to H): Representative fluorescent micrographs of platelet poor plasma from
COVID-19 patients.
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
9
Figure 4: Fibrous or cellular deposits in the plasma smears of COVID-19 patients.
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
10
Figure 5A and B: Amyloid % area in platelet poor plasma smears with mean and SEM
(p = <0.0001). A) All controls and all COVID-19 patients. B) All controls vs 10 mild
and 10 moderate to severely ill patients.
Discussion
Strongly bound up with the coagulopathies accompanying severe COVID-19 disease
is the presence of hyperferritinaemia (in cases such as the present it is a cell damage
marker (28)) and a cytokine storm, (29-33) which usually occurs in the later phase of
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
11
the disease (16). Excess iron has long been known to cause blood to clot into an
anomalous form (34), later shown to be amyloid in nature (18-24). These kinds of
phenomena seem to accompany essentially every kind of inflammatory disease (e.g.
(35)), but the amyloidogenic coagulopathies are normally assessed following the ex
vivo addition of thrombin to samples of plasma.
Many clinical features of COVID-19 are unprecedented, and here we demonstrate yet
another: the presence in platelet poor plasma to which thrombin has not been added
of amyloid microclots. This kind of phenomenon explains at once the extensive
microclotting that is such a feature of COVID-19 (8), and adds strongly to the view that
its prevention via anti-clotting agents should lie at the heart of therapy. Although
fluorescence microscopy is a specialized laboratory technique, TEG is a well-known
point of care technique, which is cheap and reliable. All told, the relative ease, speed
(40 minutes including 30 minutes ThT incubation time) and cheapness of the assay
we describe might be of considerable prognostic utility in assessing the clinical status
of COVID-19 patients.
Of course this must also be monitored (e.g. via Thromboelastography (36-39)) lest the
disease enters its later phase in which bleeding rather than clotting is the greater
danger (16). An important consideration is that TEG can be used to study the clotting
parameters of both whole blood and PPP. Whole blood TEG gives information on the
clotting potential affected by the presence of both platelets and fibrinogen, while PPP
TEG only presents evidence of the clotting potential of the plasma proteins (36-39).
Point-of-care devices and diagnostics like TEG are also particularly useful to assess
fibrinolysis. In COVID-19 patients, Wright and co-workers reported fibrinolysis
shutdown, confirmed by complete failure of clot lysis at 30 minutes on the TEG (40).
Thus TEG can therefore predict thromboembolic events in patients with COVID-19
(40). What we have shown here is that the clotting that is commonly seen in COVID-
19 patients is in an amyloid form; this alone would explain the complete shutdown of
fibrinolysis and the decreased ability to pass O2 into the blood that is such a feature of
the disease. Consequently, its prevention must lie at the heart of therapies.
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
12
DECLARATIONS
Funding
We thank the Medical Research Council of South Africa (MRC) (Self-Initiated Research
Program: A0X331) for supporting this collaboration. DBK thanks the Novo Nordisk Foundation
for funding (grant NNF10CC1016517).
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All authors approved submission of the paper.
Data sharing
https://1drv.ms/u/s!AgoCOmY3bkKHirZOu5YKPlq1x5f1AQ?e=xmWGKm
FIGURE LEGENDS
Figure 1A to D: Representative CT scans of a COVID-19 patient. Yellow arrows show
ground glass opacities.
Figure 2 A to D): Representative fluorescent micrographs of platelet poor plasma
from healthy individuals. Some signals are very slight, as shown by the arrows in A).
Figure 3A to H): Representative fluorescent micrographs of platelet poor plasma from
COVID-19 patients.
Figure 4: Fibrous or cellular deposits in the plasma smears of COVID-19 patients.
Figure 5A and B: Amyloid % area in platelet poor plasma smears with mean and SEM
(p = <0.0001). A) All controls and all COVID-19 patients. B) All controls vs 10 mild
and 10 moderate to severely ill patients.
REFERENCES
1. W. Wang et al., Detection of SARS-CoV-2 in Different Types of Clinical Specimens.
JAMA, (Mar 11, 2020).
2. J. Watson, P. F. Whiting, J. E. Brush, Interpreting a covid-19 test result. BMJ 369,
m1808 (May 12, 2020).
3. A. T. Xiao et al., Dynamic profile of RT-PCR findings from 301 COVID-19 patients in
Wuhan, China: A descriptive study. J Clin Virol 127, 104346 (Jun, 2020).
4. S. Woloshin, N. Patel, A. S. Kesselheim, False Negative Tests for SARS-CoV-2
Infection - Challenges and Implications. N Engl J Med, (Jun 5, 2020).
5. Y. Fang et al., Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR.
Radiology 296, E115 (Aug, 2020).
6. H. Meng et al., CT imaging and clinical course of asymptomatic cases with COVID-19
pneumonia at admission in Wuhan, China. J Infect 81, e33 (Jul, 2020).
7. B. Xu et al., Chest CT for detecting COVID-19: a systematic review and meta-analysis
of diagnostic accuracy. Eur Radiol, (May 15, 2020).
8. C. Willyard, Coronavirus blood-clot mystery intensifies. Nature 581, 250 (May, 2020).
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
13
9. C. Matacic, Blood vessel injury may spur disease's fatal second phase. Science 368,
1039 (Jun 5, 2020).
10. T. Kander, Coagulation disorder in COVID-19. Lancet Haematol, (Jul 10, 2020).
11. D. Liao et al., Haematological characteristics and risk factors in the classification and
prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol,
(Jul 10, 2020).
12. L. A. Teuwen, V. Geldhof, A. Pasut, P. Carmeliet, COVID-19: the vasculature
unleashed. Nat Rev Immunol 20, 389 (Jul, 2020).
13. E. Yuriditsky et al., Thromboelastography Profiles of Critically Ill Patients With
Coronavirus Disease 2019. Crit Care Med, (Jun 26, 2020).
14. H. Al-Samkari et al., COVID and Coagulation: Bleeding and Thrombotic Manifestations
of SARS-CoV2 Infection. Blood, (Jun 3, 2020).
15. A. Dorgalaleh, Bleeding and Bleeding Risk in COVID-19. Semin Thromb Hemost, (Jun
8, 2020).
16. C. Grobler et al., COVID-19: The Rollercoaster of Fibrin(ogen), D-dimer, von
Willebrand Factor, P-selectin and Their Interactions with Endothelial Cells, Platelets
and Erythrocytes. Int J Mol Sci 21, 5168 (2020).
17. L. Zhang et al., D-dimer levels on admission to predict in-hospital mortality in patients
with Covid-19. J Thromb Haemost 18, 1324 (Jun, 2020).
18. E. Pretorius, S. Mbotwe, J. Bester, C. J. Robinson, D. B. Kell, Acute induction of
anomalous and amyloidogenic blood clotting by molecular amplification of highly
substoichiometric levels of bacterial lipopolysaccharide. J R Soc Interface 123,
20160539 (2016).
19. E. Pretorius et al., Both lipopolysaccharide and lipoteichoic acids potently induce
anomalous fibrin amyloid formation: assessment with novel Amytracker™ stains.
bioRxiv preprint. bioRxiv, 143867 (2017).
20. S. de Villiers, J. Bester, D. B. Kell, E. Pretorius, Erythrocyte health and the possible
role of amyloidogenic blood clotting in the evolving haemodynamics of female
migraine-with-aura pathophysiology: Results from a pilot study. Frontiers Neurol 10,
1262 (2019).
21. E. Pretorius, M. J. Page, L. Engelbrecht, G. C. Ellis, D. B. Kell, Substantial fibrin
amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent
stains. Cardiovasc Diabetol 16, 141 (2017).
22. E. Pretorius, J. Bester, M. J. Page, D. B. Kell, The potential of LPS-binding protein to
reverse amyloid formation in plasma fibrin of individuals with Alzheimer-type dementia.
Frontiers Aging Neurosci 10, 257 (2018).
23. D. B. Kell, E. Pretorius, To what extent are the terminal stages of sepsis, septic shock,
SIRS, and multiple organ dysfunction syndrome actually driven by a toxic
prion/amyloid form of fibrin? Semin Thromb Hemost 44, 224 (2018).
24. D. B. Kell, E. Pretorius, Proteins behaving badly. Substoichiometric molecular control
and amplification of the initiation and nature of amyloid fibril formation: lessons from
and for blood clotting. Progr Biophys Mol Biol 123, 16 (2017).
25. E. Pretorius et al., Both lipopolysaccharide and lipoteichoic acids potently induce
anomalous fibrin amyloid formation: assessment with novel Amytracker™ stains. J R
Soc Interface 15, 20170941 (2018).
26. M. Francone et al., Chest CT score in COVID-19 patients: correlation with disease
severity and short-term prognosis. Eur Radiol, (Jul 4, 2020).
27. G. Goshua et al., Endotheliopathy in COVID-19-associated coagulopathy: evidence
from a single-centre, cross-sectional study. Lancet Haematol, (Jun 30, 2020).
28. D. B. Kell, E. Pretorius, Serum ferritin is an important disease marker, and is mainly a
leakage product from damaged cells. Metallomics 6, 748 (2014).
29. G. Chen et al., Clinical and immunological features of severe and moderate
coronavirus disease 2019. J Clin Invest 130, 2620 (May 1, 2020).
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint
14
30. J. Gómez-Pastora et al., Hyperferritinemia in critically ill COVID-19 patients - Is ferritin
the product of inflammation or a pathogenic mediator? Clin Chim Acta 509, 249 (Jun
21, 2020).
31. M. Vargas-Vargas, C. Cortés-Rojo, Ferritin levels and COVID-19. Rev Panam Salud
Publica 44, e72 (2020).
32. P. Mehta et al., COVID-19: consider cytokine storm syndromes and
immunosuppression. Lancet 395, 1033 (Mar 28, 2020).
33. P. Ruscitti et al., Severe COVID-19 and related hyperferritinaemia: more than an
innocent bystander? Ann Rheum Dis, (May 20, 2020).
34. E. Pretorius, N. Vermeulen, J. Bester, B. Lipinski, D. B. Kell, A novel method for
assessing the role of iron and its functional chelation in fibrin fibril formation: the use
of scanning electron microscopy. Toxicol Mech Methods 23, 352 (Jan 2, 2013).
35. D. B. Kell, E. Pretorius, No effects without causes. The Iron Dysregulation and Dormant
Microbes hypothesis for chronic, inflammatory diseases. Biol Rev 93, 1518 (2018).
36. V. G. Nielsen et al., Qualitative thrombelastographic detection of tissue factor in human
plasma. Anesth Analg 104, 59 (Jan, 2007).
37. V. G. Nielsen, J. K. Kirklin, H. Hoogendoorn, T. C. Ellis, W. L. Holman,
Thrombelastographic method to quantify the contribution of factor XIII to coagulation
kinetics. Blood Coag Fibrinol 18, 145 (Mar, 2007).
38. V. G. Nielsen, Beyond cell based models of coagulation: analyses of coagulation with
clot "lifespan" resistance-time relationships. Thromb Res 122, 145 (2008).
39. V. G. Nielsen, Effects of purified human fibrinogen modified with carbon monoxide and
iron on coagulation in rabbits injected with Crotalus atrox venom. J Thromb
Thrombolysis 44, 481 (Nov, 2017).
40. F. L. Wright et al., Fibrinolysis Shutdown Correlation with Thromboembolic Events in
Severe COVID-19 Infection. J Am Coll Surg 231, 193 (Aug, 2020).
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 29, 2020. .https://doi.org/10.1101/2020.07.28.20163543doi: medRxiv preprint